IV Vitamin C for Pancreatic Cancer: The Trial That Doubled Survival
A Phase II RCT at the University of Iowa doubled overall survival in metastatic pancreatic cancer when high-dose IV vitamin C was added to chemotherapy. The full evidence breakdown.
⭐ Grade A: Strong EvidenceThe Bottom Line
The University of Iowa Phase II RCT is the strongest single piece of evidence for any repurposed cancer treatment: high-dose IV vitamin C added to chemotherapy doubled overall survival in metastatic pancreatic cancer. This is remarkable because pancreatic cancer is one of the deadliest cancers, with typical survival of 8-12 months on standard chemo. Here's the full data.
Why Pancreatic Cancer Matters
Pancreatic ductal adenocarcinoma (PDAC) has a 5-year survival rate of ~12%. For metastatic disease, median survival with the best available chemotherapy (FOLFIRINOX or gemcitabine/nab-paclitaxel) is approximately 8-12 months. Very few interventions have moved this needle significantly. The Iowa trial did.
The Iowa Phase II RCT (2024)
- Institution: University of Iowa Holden Comprehensive Cancer Center
- Design: Phase II randomized controlled trial
- Patients: Metastatic pancreatic cancer
- Treatment arm: Gemcitabine/nab-paclitaxel + high-dose IV vitamin C (75-100g per infusion, 3x/week)
- Control arm: Gemcitabine/nab-paclitaxel alone
- Result: Overall survival was doubled in the IVC arm
- Safety: IVC was well-tolerated with no significant additional toxicity beyond standard chemo side effects
The Mechanism in Pancreatic Cancer
Pancreatic cancer cells are particularly vulnerable to IVC because:
- High intracellular iron: PDAC cells accumulate excess iron, which reacts with hydrogen peroxide generated by IVC through Fenton chemistry, creating lethal hydroxyl radicals inside the cancer cell
- Low catalase: Pancreatic cancer cells have low levels of catalase (the enzyme that neutralizes H2O2), making them unable to defend against the oxidative attack
- Normal cells are protected: They have adequate catalase and normal iron levels
Earlier Pancreatic Cancer Data
- Phase I/IIa (Nature Scientific Reports 2017): IVC + gemcitabine in pancreatic cancer. Median overall survival 15.1 months vs. historical ~6 months. Also showed decreased metastasis markers (MMP-2 and MMP-9).
- Case series: Multiple reports of prolonged survival and improved quality of life in pancreatic cancer patients receiving IVC alongside standard therapy
Practical Information
- Dose: 75-100g per infusion, 2-3 times per week
- Duration: Continuous alongside chemotherapy
- Cost: $100-250 per infusion at integrative oncology clinics
- G6PD screening REQUIRED: Must test for G6PD deficiency before starting. Hemolytic crisis can occur in deficient individuals.
- Where to find: Many integrative oncology clinics offer IVC. The Iowa trial has increased oncologist awareness.
Our Assessment
This is the strongest evidence on our entire site. Doubling survival in metastatic pancreatic cancer is an extraordinary result. The mechanism is well-characterized, the safety profile is excellent (with G6PD screening), and it's available right now at integrative oncology clinics. Anyone with pancreatic cancer should discuss this with their oncologist. The main barrier is that IVC requires clinic visits for infusions, which adds logistical burden to an already difficult treatment journey.
Sources
- University of Iowa Phase II RCT (2024): medicine.uiowa.edu
- Nature Scientific Reports 2017;7:17188: Phase I/IIa IVC + gemcitabine in pancreatic cancer
- Full High-Dose IV Vitamin C Review (Grade A)
Medical Disclaimer: This is a research review, not medical advice. Always consult with qualified healthcare professionals before making any changes to your health regimen.
How we grade evidence: Grade A = Phase II+ RCT with positive signal. Grade B = Phase I/II or strong epidemiology. Grade C = Preclinical only. Debunked = Retracted or disproven. Full methodology →